Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
Trial details
- Registry ID
- NCT06279871
- Drugs studied
- ARCT-2303, Influenza vaccine, Influenza vaccine, adjuvanted
TrialRedline tracks 6 clinical trials sponsored by Arcturus Therapeutics, Inc.: 1 Phase 3, 5 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in AdultsNCT06279871 | ARCT-2303, Influenza vaccine, Influenza vaccine, adjuvanted | Completed | 2024-10-09Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic FibrosisNCT06747858 | ARCT-032 | Recruiting | 2027-06Estimated |
| A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCDNCT06488313 | ARCT-810 | Recruiting | 2026-06-01Estimated |
| Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810NCT05526066 | ARCT-810 | Terminated | 2024-10-31Actual |
| A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy AdultsNCT04668339 | ARCT-021 single dose priming, ARCT-021 two higher dose priming, ARCT-021 two lower dose priming, Randomized booster | Terminated | 2022-03-01Actual |
| Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021NCT04728347 | ARCT-021 | Terminated | 2021-12-28Actual |
Names as written in the registry records.
NCT06747858 · Arcturus Therapeutics, Inc.
Before: 12 participants (planned). After: 33 participants (planned).
Before: Dec 2025. After: Jun 2027.
NCT06279871 · Arcturus Therapeutics, Inc.
Before: 1499 participants (actual). After: 1514 participants (actual).